Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from ritonavir-boosted protease inhibitor regimens to FTC/RPV/TDF in virologically suppressed HIV-1 patients
2010-023178-37Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of subjects with HIV-1 RNA <50 copies/mL at Week 24. Started Nov 2010; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-023178-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023178-37.